Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.

摘要: // Bo Cheng 1, 2 , Guosheng Yang 2, 3 Rui Jiang 1 Yong Haifan Lijun Pei Xiaofu Qiu Department of Urology, The Affiliated Hospital Southwest Medical University, Luzhou 646000, China Southern Guangzhou 510280, Guangdong No.2 Provincial People’s Hospital, 510317, Correspondence to: Yang, email: 2008yangguosheng@sina.com Jiang, jiangrui@126.com Keywords: renal cancer, prognosis, cancer stem cells, biomarker, meta-analysis Received: March 31, 2016     Accepted: August 10, Published: 29, 2016 ABSTRACT Background: Relevant markers CSCs may serve as prognostic biomarkers RCC. However, their actual significance remains inconclusive. Thus, a was performed to reevaluate the association CSCs-relevant (CXCR4, CD133, CD44, CD105) expression with RCC prognosis more precisely. Methods: PubMed and Embase were searched look for eligible studies. pooled hazard ratios (HR) 95% confidence intervals (95% CI) used reassess overall survival (OS), cancer-specific (CSS), disease-free (DFS), progression-free (PFS). Results: There 25 relevant articles, encompassing 2673 patients, meta-analysis. Overall analysis suggested that high predicted poor OS (HR, 2.10, CI: 1.73–2.55) DFS 3.77, 2.30–6.19). High CXCR4 worse 2.57, 1.95–3.40), CSS (HR,1.97, 1.50–2.59), 5.82, 3.01–11.25). CD44 over-expression correlated OS(HR,1.58, 1.14–2.18), 2.58, 1.27–5.23), 4.49, 2.12–9.53) in patients. CD133 an independent favorable factor 0.4, 0.29–0.54). Conclusions: presence correlates outcome. be potentially utilized stratify probably representing also novel potential therapeutic target.